Effectiveness of Topical Glycerine Sulphate Paste, Hirudoid Cream and Nil Application on Superficial Phlebitis
This study has been completed.
Sponsor:
Tan Tock Seng Hospital
Information provided by:
Tan Tock Seng Hospital
ClinicalTrials.gov Identifier:
NCT01226069
First received: October 20, 2010
Last updated: NA
Last verified: October 2010
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of the interventional study is to compare the different treatment modalities in reducing erythema size and rate of resolving phlebitis.
| Condition | Intervention |
|---|---|
|
Infection |
Drug: Glycerine Magnesium sulphate paste Drug: Mucopolysaccharide polysulphate Other: No application |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | To Investigate the Effectiveness of Topical Glycerine Sulphate, Hirudoid Cream and Nil Application in Treating Peripheral Cannula Related Phlebitis |
Resource links provided by NLM:
Further study details as provided by Tan Tock Seng Hospital:
Primary Outcome Measures:
- Erythema size [ Time Frame: 5 days ] [ Designated as safety issue: Yes ]The incremental percentage change in erythema size
Secondary Outcome Measures:
- Time to resolve redness [ Time Frame: 5 days ] [ Designated as safety issue: Yes ]The rate of phlebitis resolution
| Enrollment: | 147 |
| Study Start Date: | November 2009 |
| Study Completion Date: | February 2010 |
| Primary Completion Date: | February 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Glycerine Magnesium Sulphate paste |
Drug: Glycerine Magnesium sulphate paste
Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
|
|
Active Comparator: Hirudoid cream
Topical Mucopolysaccharide polysulphate
|
Drug: Mucopolysaccharide polysulphate
Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
|
|
Experimental: No application
Patient will not receive any topical application to apply on the phlebitis site. The outcome assessor will monitor regularly at pre-determined schedule as patients in other active arms.
|
Other: No application
No application
|
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients admitted to the study institution between Dec 2009 and Feb 2010 and observed to develop redness associated with peripheral infusion cannula.
Exclusion Criteria:
- Thrombosis, poor skin condition, and pus seen at the previous puncture.
Contacts and Locations
More Information
Publications:
| Responsible Party: | Isabel Ng Hui Leng, Tan Tock Seng Hospital |
| ClinicalTrials.gov Identifier: | NCT01226069 History of Changes |
| Other Study ID Numbers: | D/09/481 |
| Study First Received: | October 20, 2010 |
| Last Updated: | October 20, 2010 |
| Health Authority: | Singapore: Domain Specific Review Boards Singapore: Health Sciences Authority |
Keywords provided by Tan Tock Seng Hospital:
|
superficial phlebitis cannula-related vein inflammation Glycerine magnesium sulphate Hirudoid cream Nursing |
Additional relevant MeSH terms:
|
Phlebitis Peripheral Vascular Diseases Vascular Diseases Cardiovascular Diseases Vasculitis Glycerol Magnesium Sulfate Cryoprotective Agents Protective Agents Physiological Effects of Drugs Pharmacologic Actions Analgesics Sensory System Agents |
Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses Anesthetics Central Nervous System Depressants Anti-Arrhythmia Agents Cardiovascular Agents Anticonvulsants Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Tocolytic Agents Reproductive Control Agents |
ClinicalTrials.gov processed this record on May 23, 2013